Navigation Links
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol(TM) has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.

"The decision by the FDA to grant Rhitol(TM) orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.

About Rhitol(TM)

Rhitol(TM) is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol(TM) treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.

About chronic GvHD

GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient's tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as ster
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 20, 2014 BlueInGreen, LLC ... Solutions, LLC (Pinnacle), and PCI, Inc., leading suppliers ... they have been selected to provide a new ... Arkansas Paul R. Noland Wastewater Treatment. The ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals ... announce that it has closed a brokered private ... for approximately C$3.7 million.  Cormark Securities Inc. and ... the Brokered Offering for a syndicate of agents ... Financial Corp. (collectively the "Agents"). Concurrently with the ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 ... open architecture blade-based and rackmount computing infrastructure, today ... K80 dual-GPU accelerator throughout its GPU-enabled blade server ... of the company’s latest proprietary 80-lane Gen3 PCIe ... discrete NVIDIA Tesla K80 dual-GPU accelerator cards in ...
(Date:11/18/2014)... Brothers Josh and Bryce Benbasat (ages 15 ... Curing Cancer, Inc . in recognition of National Pet ... is dedicated to raising funds for pet cancer research. ... University of Florida College of Veterinary Medicine . “We ... the recipient of this vital funding. It will be ...
Breaking Biology Technology:City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... Eastland as Chief Financial Officer and Vice President, ... responsibilities will include financial management, investor relations and ... than 25 years of financial management experience to ...
... -- Chemists at Indiana University Bloomington have designed a molecule ... to release the ions in the presence of ultraviolet light. ... Society today (online), IU Bloomington chemist Amar Flood and ... how it works and, just as importantly, how they know ...
... Innovations (MBI) will be showcasing Zequanox ,™ ... at the International Conference on Aquatic Invasive Species ... September 2, 2010.  The conference is attended by participants ... and other stakeholders involved in the issues of aquatic ...
Cached Biology Technology:ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER 2IU chemists develop new 'light switch' chloride binder 2IU chemists develop new 'light switch' chloride binder 3Marrone Bio Innovations to Present Invasive Mussel Control Solution 2
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... The genome of Medicago , a close relative of alfalfa ... been sequenced by an international team of scientists, capturing around 94 ... insights into the evolution of the Papilionoid subfamily of ... Plants in this family can house and work with ...
... SALT LAKE CITY While previous studies have linked ... disease, new research at the Intermountain Medical Center Heart ... to the onset of a dangerous heart condition known ... the flagship facility for the Intermountain Healthcare system, studied ...
... Ditching the diet for Thanksgiving? Turkey with all ... to miss their goals, according to a new Cornell ... subconsciously bending willpower every day. "We,re slaves to ... and of psychology at Cornell, who co-authored the article ...
Cached Biology News:Genome sequence sheds new light on how plants evolved nitrogen-fixing symbioses 2New study links excessive amounts of vitamin D to onset of atrial fibrillation 2New study links excessive amounts of vitamin D to onset of atrial fibrillation 3
... Protein DetectorTM Microarray Dot Blot Kits overcome ... and quantitation over a wide range in ... ) detection. They are ideal for ... hundreds of samples for the presence of ...
... DNAscope LM is a high quality microarray scanner ... optimal background rejection and spatial resolution. The ... only low cost microarray scanner that is upgradeable ... Main Features: Includes control module ...
... Blot Kits overcome this limitation and offer ... wide range in low-density protein array (96- ... are ideal for performing reverse-phase protein arrays ... the presence of low abundant antigens. Protein ...
... for arraying proteins of interest with ... equipment. DiscoverLight Protein Array Kits allow ... cell lysate or antibody in a ... specially designed nitrocellulose membranes with a ...
Biology Products: